Research programme: coronary heart disease - Myriad Pharmaceuticals/Novartis

Drug Profile

Research programme: coronary heart disease - Myriad Pharmaceuticals/Novartis

Alternative Names: CHD1 gene; Coronary heart disease research programme - Myriad Genetics/Novartis; ZNF 202 gene

Latest Information Update: 10 Aug 2007

Price : $50

At a glance

  • Originator Myriad Pharmaceuticals; Novartis
  • Developer Myriad Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders; Hyperlipidaemia

Most Recent Events

  • 10 Aug 2007 Discontinued - Preclinical for Hyperlipidaemia in USA (unspecified route)
  • 10 Aug 2007 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
  • 04 Mar 2003 No development reported - Preclinical for Hyperlipidaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top